Showing posts with label remission. Show all posts
Showing posts with label remission. Show all posts

Friday, February 8, 2013

Targeted anti-vascular therapies for ovarian cancer: current evidence.


Targeted anti-vascular therapies for ovarian cancer: current evidence.


Feb 2013

Source

Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.
Abstract
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.

Sunday, January 6, 2013

Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer.


Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer.


Jan 2013

Source

Department of Surgery, Division of Gynecologic Oncology, City of Hope, 1500 E. Duarte Road, Duarte, CA, 91010, USA, ehan@coh.org.

Abstract


OPINION STATEMENT: Treatment of epithelial ovarian cancer involves surgical management with staging or debulking surgery and chemotherapy with a platinum and taxane-containing regimen. Despite achieving a 70-80 % complete remission, patients often will recur. Novel therapies are needed to improve the treatment of ovarian cancers. Tumor angiogenesis is a critical process involved in the growth and metastasis of ovarian cancer. Numerous phase II trials with angiogenesis inhibitors have been reported and have led to the development and completion of several recent phase III trials in both upfront and recurrent ovarian cancers. Future studies will need to focus on how and when to incorporate angiogenesis inhibitors in the treatment armamentarium for ovarian cancers.